Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Eptacog Beta Beyond Labels: Spanish Real-World Evidence
- 8 patients | 2 Madrid centres | 3 rare bleeding disorders
- On-Label Treatments (HA + Inhibitors; n=4)
- 3/4 on concurrent emicizumab (excluded from PERSEPT trials)
- Dosing: 75 µg/kg
- Breakthrough control + thrombotic safety
- Severe iliopsoas haematoma: 70 infusions → complete resolution, zero thrombotic events
Off-Label Treatments (n=4)
- Factor VII deficiency (n=3): Perioperative surgery with 15–20 µg/kg—excellent haemostasis, zero bleeding complications
- Steroid-refractory acquired haemophilia (n=1): High-titre inhibitor case reflects poor-prognosis disease biology
No Safety Signal: Zero thrombotic/thromboembolic complications across all patients
As emicizumab, concizumab, marstacimab and fitusiran transform prophylaxis of haemophilia, eptacog beta emerges as a versatile rescue therapy.
This real-world experience expands treatment paradigms beyond current labels—pending validation from further studies.
Congratulations to the authors!”
Read the full article here.
Article: Real-World Experience with Eptacog Beta for On-Label and Off-Label Indications: The Spanish Experience
Authors: Jose Manuel Martin de Bustamante, María Isabel Rivas-Pollmar, Natalia Acedo, Nora Butta, Victor Jimenez-Yuste, Maria Teresa Álvarez-Román
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 8, 2026, 05:53Excellent PhD Defense by Roberta Cirsmaru on Gene Therapy for Hemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Jul 8, 2026, 05:48Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
-
Jul 8, 2026, 05:39Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis
-
Jul 8, 2026, 04:50Reza Bavarsad Shahripour: New AHA Guidance on Cryptogenic Stroke with Reduced Left Ventricular Function
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism
-
Jul 7, 2026, 23:03Roxana González Mazarío: The Phenotype-Specific Cardiovascular Risks in AAV
-
Jul 7, 2026, 22:52Harry Spoelstra: LongC0VID Still has Zero Proven Treatments
-
Jul 7, 2026, 22:39Satya K. Morar: Acute Portal Vein Thrombosis as an Exceptionally Rare Complication of Liver Biopsy in CVID
-
Jul 7, 2026, 22:23Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’